Saniona publishes its interim report for the first quarter of 2023

MAR
Q1 2023 (2022)
Revenue was SEK 2.2 M (6.6 M)
Operating profit/loss was SEK -21.1 M (-133.2 M)
Net profit/loss was SEK -21.7 M (-133.4 M)
Basic earnings/loss per share was SEK -0.35 (-2.14)
Diluted earnings/loss per share were SEK -0.35 (-2.14)

Business highlights in Q1 2023

  • On January 17, Saniona announced successful preclinical in vivo validation for treatment of migraine in the Cephagenix joint venture program.
  • On February 25, Saniona announced that its partner Medix received favorable opinion for tesofensine for the treatment of obesity and weight management in Mexico.

Significant events after the reporting period

  • There have been no events after the reporting period.

Comments from the CEO
“Good progress on partnering negotiations and a potential approval of tesofensine in Mexico for treatment of obesity.”

Datum 2023-05-25, kl 08:00
Källa MFN
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.